Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity

Javitt, JC., Zlateva, GP., Earnshaw, S., Pleil, AM., Graham, C., Brogan, A., Shah, SN., & Adamis, AR. (2008). Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity. Value in Health, 11(4), 563-574.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

What's in a name? A data-driven method to identify optimal psychotherapy classifications to advance treatment research on co-occurring PTSD and substance use disorders
Article

Grandi Byen-supporting child growth and development through integrated, responsive parenting, nutrition and hygiene
Article

Effects of additional context information in prescription drug information sheets on comprehension and risk and efficacy perceptions
Article

"Show Me the Energy Costs"